- Home
- CPS vs ACIU Comparison
CPS vs ACIU Comparison
Compare CPS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPS
- ACIU
- Stock Information
- Founded
- CPS 1960
- ACIU 2003
- Country
- CPS United States
- ACIU Switzerland
- Employees
- CPS N/A
- ACIU N/A
- Industry
- CPS Auto Parts:O.E.M.
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- CPS Consumer Discretionary
- ACIU Health Care
- Exchange
- CPS Nasdaq
- ACIU Nasdaq
- Market Cap
- CPS 208.1M
- ACIU 173.7M
- IPO Year
- CPS N/A
- ACIU 2016
- Fundamental
- Price
- CPS $25.94
- ACIU $1.66
- Analyst Decision
- CPS Hold
- ACIU Strong Buy
- Analyst Count
- CPS 1
- ACIU 2
- Target Price
- CPS $12.00
- ACIU $10.00
- AVG Volume (30 Days)
- CPS 541.6K
- ACIU 137.1K
- Earning Date
- CPS 05-01-2025
- ACIU 04-30-2025
- Dividend Yield
- CPS N/A
- ACIU N/A
- EPS Growth
- CPS N/A
- ACIU N/A
- EPS
- CPS N/A
- ACIU N/A
- Revenue
- CPS $2,721,537,000.00
- ACIU $32,014,254.00
- Revenue This Year
- CPS $5.20
- ACIU N/A
- Revenue Next Year
- CPS $6.33
- ACIU $676.94
- P/E Ratio
- CPS N/A
- ACIU N/A
- Revenue Growth
- CPS N/A
- ACIU 91.20
- 52 Week Low
- CPS $10.38
- ACIU $1.43
- 52 Week High
- CPS $25.83
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- CPS 83.12
- ACIU 44.86
- Support Level
- CPS $14.02
- ACIU $1.55
- Resistance Level
- CPS $14.96
- ACIU $1.79
- Average True Range (ATR)
- CPS 1.42
- ACIU 0.10
- MACD
- CPS 1.48
- ACIU 0.03
- Stochastic Oscillator
- CPS 97.45
- ACIU 61.76
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.